(Sharecast News) - ValiRx confirmed on Friday that Ambrose Healthcare has exercised its option to license the VAL401 oncology asset, in a deal worth up to £16m plus royalties.
The AIM-traded firm said the agreement, signed via ValiRx's joint venture subsidiary ValiSeek, would include milestone payments and a commitment by Ambrose...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE